<DOC>
	<DOCNO>NCT00778206</DOCNO>
	<brief_summary>The objective study evaluate safety long-term treatment Kuvan .</brief_summary>
	<brief_title>PKUDOS : Phenylketonuria ( PKU ) Demographic , Outcomes , Safety Registry</brief_title>
	<detailed_description>The PKUDOS program voluntary , multicenter , strictly observational program patient PKU either receive Kuvan therapy , currently receive Kuvan , intend begin receive Kuvan therapy within 90 day enter registry .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>PKUDOS Registry Patient confirm diagnosis PKU hyperphenylalaninemia document Phenylalanine level great equal 360 umol/L ( 6 mg/dL ) Patient previously receive Kuvan Patient currently receive Kuvan Patient intend receive Kuvan therapy within 90 day enrollment registry The Patient follow PKUDOS participate center Willing able provide write authorization , age 18 year , provide write assent ( require ) write patient authorization parent legal guardian Willing provide personal health information Patients eligible participate PKUDOS participating BioMarinsponsored clinical study Kuvan Patients previously treat Kuvan patient unwilling begin Kuvan therapy within 90 day entry registry PKU MOMS Subregistry Willing enroll ( already enrol ) PKUDOS Agree follow standard care pregnant woman PKU United States ( NIH , 200 , NIH Consensus Statement ) Agree follow hospital PKU clinic offer standard care maternal PKU Are within 10 week last menstrual period Patients adhere standard care pregnant woman PKU United States eligible participate PKU MOMS</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Phenylketonuria</keyword>
	<keyword>Hyperphenylalaninemia</keyword>
	<keyword>PKU</keyword>
	<keyword>Phenylalanine</keyword>
</DOC>